新闻NewLink Genetics Corporation received financing of $7.5M in Series D on Feb 15th '23.NewLink Genetics Corporation announced today that it has secured $7.5 million in a Series D financing to accelerate the clinical development of its therapeutic cancer products.
新闻NewLink Genetics Corporation partnered with Merck on Dec 1st '16.For instance, in December 2016, a study published in The Lancet, reported that rVSV-ZEBOV, also known as V920 vaccine, jointly developed by Newlink Genetics and Merck and Company, was effective in protection against Ebola virus disease.
新闻NewLink Genetics Corporation merged with Lumos Pharma, Inc. on Sep 30th '19.As previously reported, on September 30, 2019, NewLink announced its intent to merge with Lumos Pharma, a private clinical-stage biopharmaceutical company targeting rare and neglected diseases.
